AMERICAN ASSOCIATION FOR CANCER RESEARCH
86th Annual Meeting

Donald S. Coffey, Program Chairperson
Metro Toronto Convention Centre, Toronto, Ontario, Canada
March 18-22, 1995

Titles of Major Sessions
(Confirmed Chairpersons in Parentheses)

PLENARY SESSION
An Integrated View of the Cancer Cell (Donald S. Coffey)

SYMPOSIA
The Cell Cycle and Tumor Suppressor Genes (Thea D. Tlsty)
DNA Damage and Repair (Philip C. Hanawalt)
Natural Products in Chemoprevention of Cancer (Michael B. Sporn)
Ribozymes and Antisense Oligonucleotides and the Alteration of Gene Expression (Kevin J. Scanlon)
Genetic Susceptibility to Cancer (Kenneth W. Kinzler)
Contributions of Environmental Factors to Cancer (Kenneth Olden)
Cell Surface Glycosylation Defining Malignancy (Sen-itiroh Hakomori)
Peripheral Stem Cells and High-Dose Chemotherapy (Peter J. Quesenberry)
Apoptosis (Alan R. Eastman)
Biological Radiation Oncology (H. Rodney Withers and C. Norman Coleman)
Biomarkers of Carcinogenesis (David Sidransky)
Transcription Factors and Carcinogenesis (Frank J. Rauscher III)
Gene Therapy in Cancer Clinical Trials
Telomeres and Telomerases (Carol W. Greider and Jerry W. Shay)
Extracellular Matrix, Gene Expression, and Cell Signalling (Hynda K. Kleinman)
Mechanistic Basis for Ethnic Differences in Cancer Risk (Kenneth Olden)
Signal Transduction and Gene Control and Development (James E. Darnell)
Angiogenesis (Judah Folkman and Adrian L. Harris)
Genes, Development, and Cancer (Eric N. Olson)
Growth Factors, Receptors, and Differentiation (Angie Rizzino)
New Strategies and Targets for Chemotherapy (Joseph R. Bertino and Eddie Reed)
Genetic Approaches to Invasion and Metastasis (Robert S. Kerbel and Patricia S. Steeg)
Immunotherapy: Tumor Vaccines (David A. Berd)
Graft versus Tumor Effects (Richard J. O'Reilly)
Dietary Intervention in Hormonal Carcinogenesis (Diane F. Birt and Lovell A. Jones)
The Role of Stromal-Epithelial Interactions in Growth and Neoplasia (Leland W. K. Chung)
Cancer Prevention and Intermediate Biomarkers (Peter Greenwald)
Combinatorial Chemistry for Anticancer Drug Discovery (Sydney E. Salmon)

Translational Research in Breast Cancer (Marc E. Lippman)
DNA Methylation (Peter A. Jones and Stephen B. Baylin)

METHODS WORKSHOPS
General, In Situ, and Quantitative PCR (including Differential Display) (Saraswati Sukumar)
Gene Targeting (Janet Rossant and Andras Nagy)

CONTROVERSY SESSIONS
Are Estrogens Implicated in Breast Cancer? (Lovell A. Jones)
Is Mammography Before Age 50 Beneficial? (Virginia L. Ernst)
What Are the Limits and Benefits of PSA as a Screening Tool? (John Trachtenberg)
Breast Cancer Prevention: What Will We Advise Women with BRCA1? (Louise C. Strong)
What Are the Risks of Electromagnetic Fields in Causing Cancer? (Mark A. Israel)
Is Bone Marrow Transplantation Indicated for Breast Cancer? (Nancy E. Davidson)

MEET-THE-EXPERT SUNRISE SESSIONS
New Developments in Clinical Pharmacology (Merrill J. Egorin)
Site-specific Gene Expression in Transgenic Animals (Norman Greenberg)
Organ-specific Carcinogenesis (Cheryl Lyn Walker)
Modeling and Analyzing Clinical Trials (Steven Piantadosi)
Multivariate Determinants of Radiocurability (Richard P. Hill)
Multidrug Resistance (Victor Ling)
Cytokines, Vaccines, and Gene Therapy (Jonathan W. Simons)
Tyrosine Kinases and Phosphatases
Prostate Cancer (John T. Isaacs)
Lung Cancer (Stephen B. Baylin)
Colon Cancer (Ronald N. Buick)
Pediatric Malignancies (Joseph V. Simone)
Hematological Malignancies (Lee M. Nadler)
Stem Cell Transplantation (Elizabeth J. Shpall)
Molecular Determinants of Multidrug Resistance (Elizabeth W. Newcomb)
Is a Mutagenic Event Involved in Initiation? (Ann R. Kennedy)
Glutathione S-Transferase (Kenneth D. Tew)
Farnesyl Transferase as a Target for Therapy (Alexander W. Wood)
Liver Cancer Etiology and Prevention (John D. Groopman)
Biochemical Determinants of Carcinogenesis (Allan B. Okey)

EDUCATIONAL WORKSHOPS
To Be Announced

Further Information: AACC Office • Public Ledger Building • Suite 816 • 150 S. Independence Mall West
Philadelphia, PA 19106-3483 • TELEPHONE (215) 440-9300 • FAX (215) 440-9313
THE VANDERBILT CANCER CENTER

Several tenure track faculty positions are available in the Vanderbilt Cancer Center. Positions are available at all academic ranks and carry competitive startup packages. Outstanding candidates will be considered in all fields of cancer research but priority will be given to individuals interested in the identification or functional characterization of cancer genes and in molecular epidemiology. Women and minorities are especially encouraged to apply. Investigators will have primary appointments in Medical School departments and will be housed in newly constructed Cancer Center space. Candidates should send a curriculum vitae, an outline of research plans, and three letters of recommendation to:

Chair, Faculty Search Committee
The Vanderbilt Cancer Center
876 Medical Research Building
Vanderbilt University Medical Center
Nashville, TN 37232-6838

Vanderbilt University is an equal opportunity/affirmative action employer.

THE OHIO STATE UNIVERSITY

INTERNAL MEDICINE/MEDICAL ONCOLOGY

Postdoctoral Fellowships in Oncology available beginning July 1995 and 1996 for those with M.D., D.O. or M.D./Ph.D., or Ph.D. degrees. Unique research training by interdisciplinary faculty with research interests including clinical research, developmental therapeutics, biological response modifiers, pharmacology and pharmacokinetics, hormones and cancer, cancer immunology, molecular biology and cancer control and prevention. Program prepares trainees for careers in academic or research setting focused on oncology. Contact: Stanley P. Balcerzak, M.D., The Ohio State University, N1025 Doan Hall, 410 West Tenth Avenue, Columbus, Ohio 43210.

An Equal Opportunity/Affirmative Action Program.
Minority applicants are encouraged.
MOLECULAR BIOLOGY OF CANCER: IMPLICATIONS FOR PREVENTION AND THERAPY

Third Joint Conference of the American Association for Cancer Research and the
Japanese Cancer Association

Maui Marriott Hotel, Maui, HI
February 13-18, 1995

SCIENTIFIC PROGRAM COMMITTEE

AACR
LEE W. WATTENBERG / Minneapolis
Co-Chairperson
JOSEPH R. BERTINO / New York
WEBSTER K. CAVEENE / La Jolla
WAUN KI HONG / Houston
MICHAEL B. SPORN / Bethesda

JCA
MASAKI TERADA / Tokyo
Co-Chairperson
KAORU ABE / Tokyo
YOSHIYUKI HASHIMOTO / Sendai
HIROO IMURA / Kyoto
NOBUYUKI ITO / Nagoya
TADAO KAKIZOE / Tokyo
TOMOYUKI KITAGAWA / Tokyo

Keynote Addresses
TAKASHI SUGIMURA / Tokyo
LEE W. WATTENBERG / Minneapolis

Differentiation
*TOMOYUKI KITAGAWA / Tokyo
*MICHAEL B. SPORN / Bethesda
HOYOKU NISHINO / Tokyo
LORRAINE J. GUIDAS / New York
TOSHIKO KUROKI / Tokyo
MARTIN LIPKIN / New York

Signal Transduction
*FRANK MCCORMICK / Richmond
*TAKASHI TSURUO / Tokyo
YOSHIKI TAKAI / Osaka
MASAMUNE SHIBUYA / Tokyo
I. BERNARD WEINSTEIN / New York
TADATSUGU TANIGUCHI / Osaka

Hormones and Receptors
*KUMAO TOYOSHIMA / Osaka
*BRIAN E. HENDERSON / La Jolla
MICHAEL N. GOULD / Madison
JOHN T. ISAACS / Baltimore
KEN YAMAGUCHI / Tokyo
TADAMITSU KISHIMOTO / Osaka

Multi-Step Carcinogenesis and Genomic Instability I
*HIROO IMURA / Kyoto
*WEBSTER K. CAVEENE / La Jolla
MASAKI TERADA / Tokyo
RAYMOND L. WHITE / Salt Lake City
MINAKO NAGAO / Tokyo
YUSUKE NAKAMURA / Tokyo

Multi-Step Carcinogenesis and Genomic Instability II
*ALLAN H. CONNEY / Piscataway
*HIROSHI KOBAYASHI / Sapporo
NOBUYUKI ITO / Nagoya
MUTSUO SEKIGUCHI / Fukuoka
THEA D. TLSTY / Chapel Hill
TOSHIKAZU NAKAMURA / Osaka
SHIGEKAZU NAGATA / Osaka
JOSEPH R. BERTINO / New York

Chemoprevention in Vivo
*WAUN KI HONG / Houston
*SUKETAMI TOMINAGA / Nagoya
ALLAN H. CONNEY / Piscataway
YASUTOSHI MUTSUO / Gifu
PETER GREENWALD / Bethesda
SHIGEO HINO / Yonago

Special Lecture
CARLTON GAJDUSEK / Bethesda

Genetic Intervention
*YOSHIYUKI HASHIMOTO / Sendai
*JACK S. COHEN / Rockville
MITSUHIRO YAMAGIDA / Kyoto
ERIC J. STAMBRIDGE / Irvine
RICHARD C. MULLIGAN / Cambridge
KIYOSHI TANAKA / Osaka

Scientists are encouraged to submit abstracts of papers for consideration for poster sessions. Persons in the Americas and countries other than Japan may obtain additional information from the AACR Office.

* designates Session Chairperson

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483 USA
Telephone: (215) 440-9300
FAX: (215) 440-9313

Office of the Japanese Cancer Association
for the 3rd Joint Conference
c/o National Cancer Center
5-1-1 Tsukiji, Chuo-ku
Tokyo, 104 JAPAN
Telephone: (03)-3542-2511 ext. 4101
FAX: (03)-3248-0326
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GERTRUDE ELION CANCER RESEARCH AWARD

Supported by an Educational Grant from
Wellcome Oncology
Burroughs Wellcome Co.

- This Award was established in honor of Nobel Laureate Dr. Gertrude Elion, Scientist Emeritus at the Burroughs Wellcome Co. and Past President and Honorary Member of the AACR.

- The Gertrude Elion Cancer Research Award is a one-year, $30,000 grant for a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or translational research in cancer etiology, diagnosis, treatment, or prevention at the level of Assistant Professor.

- The AACR will reimburse the Awardee for travel to the Annual Meeting where Dr. Elion will personally present this Award.

Eligibility
Candidates must have completed postdoctoral studies or clinical fellowships not later than July 1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty in academia, government employees, and employees of private industry are not eligible for this award. A Candidate need not be a member of the AACR at the time of application, but must be nominated by a Member of the AACR. Associate Members may not be nominators.

Selection Process
Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Complete applications must be submitted by January 10, 1995 to be considered for the 1995 Award.

For Further Information/Application Forms
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
ATTN.: Jenny Anne Horst-Martz
This cover features John Robin Warren (bottom right) and Barry J. Marshall (bottom left) for their pioneering discovery of Helicobacter pylori in the gastric mucosa, a key etiological agent associated with the occurrence of gastric and duodenal ulcers, and Pelayo Correa (top) for his contributions in elucidating the role of H. pylori in gastric carcinogenesis.

This major recent discovery began in 1979 when Dr. Warren, a pathologist at the Royal Perth Hospital, made the astute yet controversial observation that bacteria were proliferating on gastric mucosa, visualized by fiber-optic biopsy. He confirmed the presence of this bacterium and verified its close relationship to active chronic gastritis (Lancet, 1: 1273, 1983).

Dr. Warren had only limited clinical information with which he could link his observations until the Registrar in the Gastroenterology Department of the Royal Perth Hospital, Dr. Marshall, expressed interest in collaborating. Success ensued when culture plates produced visible colonies. Taxonomy of this gram-negative, urease-rich organism closely resembled a Campylobacter species but was later established as a new genus, Helicobacter, and named H. pylori.

A systematic evaluation of 100 consecutive patients undergoing elective gastroscopy revealed an association (Lancet, 1: 1311, 1984). Patients with gastritis, who had gastric or duodenal ulcers treated with bismuth compounds and antibiotics, not only had healing of lesions but went also into long-lasting remissions, because H. pylori was thus eliminated. Patients treated with only antacids or cimetidine almost inevitably relapsed without continued treatment, since H. pylori persisted.

Dr. Marshall infected himself with H. pylori and demonstrated its relation to inflammation in his own stomach to confirm Koch’s postulate. He was confident that he could be cured by the antibacterial treatment, and he was.

Dr. Correa, based on observation and material collected in New Orleans and Colombia, had shown that H. pylori may be an etiological factor in gastric cancer in at least 3 points of the chain of causation: (a) chronic gastritis and increased cell replication (Am. J. Gastroenterol., 88: 1870, 1993); (b) interfering with the concentration of ascorbic acid in the gastric milieu (Nutr. Cancer, 22: 65, 1994; Am. J. Gastroenterol., 89: 533, 1994); and (c) attracting and activating inflammatory cells, especially neutrophils, which may deliver “oxidative bursts” in the immediate vicinity of replicating epithelial cells, with mutagenic potential (Cancer Res., 52: 6735, 1992).

These historic findings have now been confirmed in other areas with a high incidence of gastric cancer. Now, only 11 years after the first publication by Drs. Warren and Marshall, H. pylori is accepted as a key etiological factor for gastric and duodenal ulcers and for gastric cancer. Nubia Muñoz recently reviewed the association of H. pylori infection and gastric cancer (Cancer Epidemiol., Biomarkers & Prev., 3: 445, 1994). The data provide support for the mechanistic interpretation by John Weisburger and colleagues that H. pylori acts as a cytotoxin, leading to gastric cell regeneration, and renders the mucosa more sensitive to dietary genotoxic gastric carcinogens as described by Steven R. Tannenbaum and Dr. Correa (Cancer Res., 51: 190, 1991; Chem. Res. Toxicol., 5: 797, 1992) and by the Weisburger laboratory (J. Natl. Cancer Inst., 64: 163, 1980).

Dr. Warren earned M.B. and B.S. degrees at the University of Adelaide, Australia, in 1961. He was Registrar in Hematology and Clinical Pathology in Adelaide, then Lecturer and Clinical Assistant in Pathology at the Royal Adelaide Hospital. He later became Registrar in Pathology at the Royal Melbourne Hospital and is currently a pathologist at Royal Perth Hospital. He was the guest of honor at the 6th International Workshop on H. pylori in 1991.

Dr. Marshall received M.B. and B.S. degrees from the University of Western Australia in Perth in 1974. After residencies at the Queen Elizabeth II Medical Center, he became Registrar in General Medicine and Gastroenterology at Royal Perth Hospital, where he became Clinical Research Assistant, and at Fremantle Hospital. Since 1986, he has been on the gastroenterology and internal medicine faculties at the University of Virginia Medical Center in Charlottesville, VA. He also serves as a consultant in diagnostics as President, Med Dial Corporation and Medical Director, TRI-MED Specialties, Inc. In addition, he is a founder of the Helicobacter Foundation.

Dr. Correa received his M.D. degree at the University of Antioquia, Colombia, in 1949 and did his pathology training at Emory University in Atlanta, GA. He then became Professor of Pathology at Universidad del Valle, Cali, Colombia. He served as a Visiting Fellow in Epidemiology at the National Cancer Institute in Bethesda, MD. At present, he is Professor and Chief of the Epidemiology Section in the Department of Pathology at Louisiana State University Medical Center, New Orleans, LA. He is Editor-in-Chief of Cancer Epidemiology, Biomarkers & Prevention, one of the official journals of the American Association for Cancer Research (AACR), and has served on a number of AACR committees including the International Affairs Committee and the Membership Committee.

We are indebted to those featured for photographs and information. On the cover is a photomicrograph from Dr. Warren displaying H. pylori within the gastric mucosa in one of his first historic observations (first column, top). The other photograph (by F. Hernandez) is from a scanning electron microscopic view of H. pylori obtained from Dr. Correa (first column, bottom).